BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, January 9, 2026
Home
»
Authors
» Brady Huggett
Brady Huggett
Articles
ARTICLES
Genentech Meets Estimates On Increased Rituxan Revenue
Jan. 17, 2003
By
Brady Huggett
Genentech Meets Estimates On Increased Rituxan Revenue
Jan. 17, 2003
By
Brady Huggett
Incara Making Sacrifices; Elan Declines Antioxidant Option
Jan. 16, 2003
By
Brady Huggett
Incara Making Sacrifices; Elan Declines Antioxidant Option
Jan. 16, 2003
By
Brady Huggett
Amylin Files For $141.7M Public Offering From Shelf
Jan. 14, 2003
By
Brady Huggett
Amylin Files For $141.7M Public Offering From Shelf
Jan. 14, 2003
By
Brady Huggett
ZymoGenetics, Novo Agree On $11M IL-21 Collaboratio
Jan. 10, 2003
By
Brady Huggett
ZymoGenetics, Novo Agree On $11M IL-21 Collaboratio
Jan. 10, 2003
By
Brady Huggett
Atrix Licenses Japanese Eligard Rights To Sosei In $30M Deal
Jan. 7, 2003
By
Brady Huggett
DrugAbuse Sciences' Product Shows Benefit In Phase III Trial
Jan. 7, 2003
By
Brady Huggett
View All Articles by Brady Huggett
